Dublin, March 08, 2018 -- The "Clinical Genomics Market By Test Type, Software, Method and End User - Global Opportunity Analysis and Industry Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
Global clinical genomics market is expected to reach USD 879.0 million by 2023, at a CAGR of 17.1% during the forecast period of 2018 to 2023.
The report carries out an impact analysis of the key industry drivers, restraints, opportunities, challenges, and trends in the global market. The global clinical genomics market is mainly driven by growing significance of early disease detection and prevention, rising insistence for precision medicine, increasing application of genetic testing in oncology, and favourable reimbursement scenario related to genetic testing. However, high cost and social and ethical implications of genetic testing hinder the growth of clinical genomics market to some extent.
Geographically, the global clinical genomics market is segmented into four major regions, namely North America, Europe, Asia-Pacific, and Rest of World. North America accounted for the major share in the global clinical genomics market in 2017, followed by Europe, and Asia-Pacific. The major share of the North American region is mainly attributed to the public awareness regarding genetic testing, high burden of inherited and rare disorders, increasing R&D expenditure, and various government initiatives.
On the other hand, Asia-Pacific region is projected to grow at the fastest CAGR during the forecast period, mainly due to increasing population, rising rate of diseases, and various government initiatives for the genomic research in order to understand the complex biological process and genetic mutation present in life-threatening diseases.
The geographical analysis provides detailed insights on the key trends of the industry in the listed regions, identifying the demographic & economic impact, government & private investments, market opportunities and forecast, and regulatory scenario. The geographical analysis section also comments on the key market players shaping the growth of the industry in the respective regions, market size, and forecast for clinical genomics market till 2023.
The report includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2018). The study has also incorporated the detailed profiles of 25 top market players, including detailed financial performance, strategic focus, business overviews, and product offerings of each player.
Key questions answered in the report:
- Which are the high growth market segments in terms of test type, method, end user, and regions/countries?
- What is the historical market for clinical genomics across the globe?
- What are the market forecasts and estimates from the period 2016-2023?
- What are the major drivers, restrains, opportunities, challenges and trends in the global clinical genomics market?
- Who are the major players in the global clinical genomics market and what share of the market do they hold?
- Who are the major players in various regions and what share of the market do they hold?
- What are the competitive landscapes and who are the market leaders by sub-region in the global clinical genomics market?
- What are the recent developments in the global clinical genomics market?
- What are the different strategies adopted by the major players in the global clinical genomics market?
- What are the geographical trends and high growth regions/countries?
- What are the local emerging players in the global clinical genomics market and how do they compete with the global players?
Key Topics Covered:
1. Introduction
1.1. Currency and Limitations
2. Research Methodology
3. Executive Summary
4. Market Share Analysis
5. Market Insights
5.1. Introduction
5.1.1. Drivers
5.1.1.1. Growing Significance of Early Disease Detection and Prevention
5.1.1.2. Rising Insistence for Precision Medicine
5.1.1.3. Increasing Application of Genetic Testing in Oncology
5.1.1.4. Favorable Reimbursement Scenario Related to Genetic Testing
5.1.2. Restraints
5.1.2.1. Enormous Cost of Genetic Testing
5.1.2.2. Social and Ethical Implications of Genetic Testing
5.1.3. Opportunities
5.1.3.1. Genetic Counseling
5.1.3.2. Genetic Nursing
5.1.4. Challenges
5.1.4.1. Accuracy & Standardization Concerns in Genetic Testing
5.1.5. Trends
5.1.5.1. Growing Direct to Consumer Genetic Testing
6. Clinical Genomics Market, by Product/Service Type
6.1. Introduction
6.2. Tests
6.3. Software
7. Clinical Genomics Market, by Test Type
7.1. Introduction
7.2. Diagnostic Testing
7.3. Genetic Testing
7.4. Newborn Screening
7.5. Prenatal Testing
7.6. Preimplantation Testing
7.7. Carrier Testing
7.8. Other Tests
8. Clinical Genomics Market, by Method
8.1. Introduction
8.2. Molecular Tests
8.3. Chromosomal Tests
8.4. Biochemical Tests
9. Clinical Genomics Market, by End User
9.1. Introduction
9.2. Hospitals & Clinics
9.3. Government Laboratories & Research Centers
9.4. Academic & Research Institutes
9.5. Other End-Users
10. Clinical Genomics Market, by Geography
11. Competitive Landscape
11.1. Introduction
11.2. Agreements, Collaborations, and Partnerships
11.3. New Product Launches & Enhancements
11.4. Expansions
11.5. Mergers & Acquisitions
11.6. Approvals
11.7. Other Developments
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Recent Strategic Developments)
- 23andMe, Inc.
- Beijing Genomics Institute (BGI)
- CENTOGENE AG
- Clinical Genomics Technologies Pty Ltd.
- Eurofins Scientific SE
- Foundation Medicine, Inc.
- Gene by Gene Ltd
- GenomeDx Biosciences, Inc.
- Genomic Health, Inc.
- Illumina, Inc.
- Invitae Corporation
- Iverson Genetic Diagnostics, Inc.
- MedGenome
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics, Inc.
- OPKO Health, Inc.
- Pathgroup
- PerkinElmer, Inc.
- Personalis, Inc.
- Quest Diagnostics Incorporated
- Retrogen, Inc.
- Rosetta Genomics, Ltd.
- Strand Life Sciences Pvt. Ltd.
- Veritas Genetics
For more information about this report visit https://www.researchandmarkets.com/research/2fsxtf/2018_879_million?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics


Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Nintendo Shares Jump as Switch 2 Sales Boost Earnings
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Jetstar to Charge for Overhead Cabin Bags From February
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 



